Tirzepatide benefits similar in adults 65 and older, pooled trial analysis finds
A pooled analysis of seven tirzepatide trials found adults 65 and older got weight and heart-risk benefits similar to younger adults, with no meaningful safety differences in areas like falls and fractures.
Adults 65 and older with obesity or overweight who took tirzepatide saw clinically meaningful weight reduction and favorable changes in cardiometabolic risk factors and quality-of-life measures that were broadly comparable to those seen in younger adults, according to a post hoc analysis of seven Phase 3 trials published June 16, 2026 in the journal Diabetes, Obesity and Metabolism [1].
The analysis combined data from SURMOUNT-1 through -5 (including the three-year SURMOUNT-1 study), SURMOUNT-OSA and SUMMIT. Together those trials compared tirzepatide — a once-weekly GLP-1 and GIP receptor agonist sold as Mounjaro and Zepbound — with placebo or an active comparator in adults with obesity or overweight. Some participants also had type 2 diabetes (SURMOUNT-2), heart failure with preserved ejection fraction (SUMMIT) or obstructive sleep apnea (SURMOUNT-OSA) [1]. The analysis compared participants aged 65 and older with those under 65. All seven trials are registered on clinicaltrials.gov [1].
The paper reports that tirzepatide treatment in the older group was associated with clinically meaningful weight reduction and favorable treatment differences in cardiometabolic risk factors and quality-of-life measures, with results broadly comparable to the younger group [1]. The abstract does not give a pooled average weight-loss percentage for either age group.
On safety, the researchers found no clinically meaningful differences in adverse event rates between tirzepatide and placebo among older adults for gastrointestinal tolerability, falls, fractures, depression outcomes, pancreatitis, and kidney, liver, gallbladder and biliary-related events. The authors state that no clinically relevant risks beyond those inherent to older age were detected in adults 65 and older compared with younger adults [1].
The paper notes that safety outcomes were assessed in the pooled population across the treatment period, while efficacy outcomes were analyzed study by study at different time points depending on each trial's design [1]. Because this is a post hoc analysis rather than a trial designed in advance to test older adults, the findings describe what happened in these trials; they do not establish that tirzepatide prevents falls, fractures or depression in this age group.
The authors also flag a concern specific to older patients: reduced muscle mass and anabolic resistance make this group prone to sarcopenia, and even modest muscle loss can impair physical function and worsen frailty, something the paper says "may be amplified in the context of weight reduction interventions" [1]. Effects on muscle mass are not described in the abstract.
Several co-authors are employees of Eli Lilly and Company, which makes tirzepatide, and the corresponding author is Nasreen Alfaris of King Fahad Medical City in Riyadh, Saudi Arabia. Robert F. Kushner of Northwestern University Feinberg School of Medicine is also an author [1].
Why it matters for patients
About 30% of US adults aged 65 and older have obesity, and the paper notes that older adults with obesity face not just cardiovascular and metabolic risks but also functional decline, disability and loss of independence [1]. Clinical trials have historically included fewer older adults, so data on how these drugs behave in this group has been thinner.
The safety areas the researchers checked — gastrointestinal tolerance, falls, fractures, depression, pancreatitis and organ-related events — are the ones most often raised when weighing obesity treatment in older patients. In this pooled dataset, older adults on tirzepatide did not show clinically meaningful differences from placebo in those categories beyond what is expected with age [1].
The analysis does not address cost, insurance coverage or how these results compare with semaglutide (Ozempic, Wegovy, Rybelsus) or with orforglipron (Foundayo) in older adults. No head-to-head comparison of those drugs in this age group is reported here.
What happens next
The authors conclude that the results support tirzepatide's use in older adults when risks and benefits are weighed [1]. The paper does not announce any new clinical trial, label change or regulatory filing based on this analysis, and none has been disclosed.
Dosing, eligibility and monitoring decisions remain with patients and their prescribers; the analysis does not offer dose recommendations for older adults.
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.